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Abstract: This study aimed to investigate relationships between infant abdominal visceral and
subcutaneous adiposity and human milk (HM) components and maternal body composition (BC)
during first year of lactation. Subcutaneous-abdominal depth (SAD), subcutaneous-abdominal fat
area (SFA), visceral depth (VD) and preperitoneal fat area of 20 breastfed infants were assessed
at 2, 5, 9 and 12 months using ultrasound. Maternal BC was determined with bioimpedance
spectroscopy. HM macronutrients and bioactive components concentrations and infant 24-h milk
intake were measured and calculated daily intakes (CDI) determined. Maternal adiposity associated
with infant SFA (negatively at 2, 5, 12, positively at 9 months, all overall p < 0.05). 24-h milk intake
positively associated with infant SAD (p = 0.007) and VD (p = 0.013). CDI of total protein (p = 0.013),
total carbohydrates (p = 0.004) and lactose (p = 0.013) positively associated with SFA. Lactoferrin
concentration associated with infant VD (negatively at 2, 12, positively at 5, 9 months, overall
p = 0.003). CDI of HM components and maternal adiposity have differential effects on development
of infant visceral and subcutaneous abdominal adiposity. Maintaining healthy maternal BC and
continuing breastfeeding to 12 months and beyond may facilitate favourable BC development
reducing risk of obesity.
Keywords: visceral fat; subcutaneous-abdominal fat; abdominal adiposity; human milk; lactation;
infants; body composition; intake; macronutrients; obesity
1. Introduction
Abdominal obesity is one of the facets of metabolic syndrome and is critically im-
portant in clinical diagnosis [1]. Fat distribution in this area plays an important role in
outcomes such as obesity-related morbidity and cardio metabolic risk with visceral adi-
pose tissue being the most metabolically and pro-inflammatory active fat depot [2], whilst
subcutaneous adipose tissue, specifically superficial subcutaneous adipose tissue, asso-
ciating with protection [3]. During childhood, accelerated gain in fat mass (FM) [4] and
particularly abdominal visceral fat (VF) [5,6] are considered to be a risk factor for metabolic
diseases later in life as VF in early life tracks into childhood and beyond [7–9]. Furthermore,
early sources of nutrition such as breastfeeding are implicated in development of infant
body composition (BC) [10] potentially contributing to reported associations of breast-
feeding and human milk (HM) with reduced risk of obesity and lower incidence of late
metabolic diseases, such as type 2 diabetes [11], although mechanisms of this protection
are poorly understood.
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Ultrasound has been recently validated to measure infant abdominal visceral and
subcutaneous adipose tissue, providing a non-invasive technique for determination of the
development of these fat depots during infancy [12]. One study of breastfed and formula-
fed infants during the first 6 months of life showed no significant difference in abdominal
fat distribution (subcutaneous and preperitoneal fat thickness) between the groups [13].
Contrarily, another study reported that visceral depths were lower at 3 and 12 months
of age in infants that were exclusively breastfed at 3 months, suggesting visceral and
subcutaneous-abdominal adiposities may be differentially regulated during infancy [12].
Furthermore, the duration of exclusive breastfeeding was found to relate positively to
percentage fat mass (%FM) and subcutaneous, but not VF [14], with maternal factors
having no effect on development of these fat depots; however, infants were followed up
to 6 months only, with 38% exclusively breastfed at 3 months of age (19% at 6 months).
The only study that investigated effect of HM macronutrient composition on infant ab-
dominal adiposity showed positive relationships between HM fat concentration and infant
abdominal subcutaneous fat thickness, but negative between protein concentration and VF
thickness [15].
It is still not understood how breastfeeding and particularly the doses (daily intakes)
of HM components influence the acquisition and distribution of abdominal subcutaneous
and VF in infants that are breastfed on demand beyond the exclusive breastfeeding period.
Establishing the modifiable determinants that influence adiposity and FM development in
infancy can inform the support of optimal infant development.
The main aim of this pilot longitudinal study was to evaluate relationships of HM
macronutrients (casein, total and whey protein, total carbohydrates and lactose), appetite
hormones (adiponectin and leptin) and immune factors (lactoferrin, lysozyme, secretory
IGA (sIgA) and HM oligosaccharides (HMO; calculated)) that are present in HM in sub-
stantial quantities, with development of abdominal subcutaneous and VF depots in healthy
term breastfed infants during the first 12 months of lactation. We also investigated the
relationships of these fat depots with maternal BC and with infant 24-h milk intake and
breastfeeding frequency.
2. Materials and Methods
2.1. Subjects and Design
This longitudinal observational study included 20 healthy term infants and their moth-
ers who exclusively breastfed to 5 months and continued breastfeeding on demand until
12 months. Mothers were recruited from the community and visited our research laboratory
at King Edward Memorial Hospital for Women (Subiaco, Perth, WA, Australia) between
March 2013 and September 2015 for up to four measurement sessions (2, 5, 9 and 12 months
postpartum) (Figure A1). Eligibility criteria: healthy singletons, gestational age ≥37 weeks,
exclusively breastfed to 5 months, breastfed at 9 and 12 months. Exclusion criteria: infant
health issues potentially influencing growth and development, formula supplementation
at any time, maternal low milk supply and smoking. Women provided written informed
consent for participation in the study that was approved by The University of Western Aus-
tralia Human Research Ethics Committee (RA/4/1/4253, RA/4/1/2639) and registered
with Australian New Zealand Clinical Trials Registry (ACTRN12616000368437).
Milk samples were collected and infant abdominal adiposity together with maternal
anthropometrics and BC were determined when the infants were 2, 5, 9 and 12-month-
old. Dyads were healthy at the time of the visit (no infectious illness, such as cold or
flu, no indication of mastitis in mothers at the time of study visit). 24-h milk intake and
breastfeeding frequency (meals/24-h) were determined by mothers at home using infant
test-weighing before and after breastfeeding between 2 and 5 months, when lactation is
stable, and again within 2 weeks of 9 and 12 months [16,17]. Mothers also self-reported
breastfeeding frequency at the study visits as the current typical time (hours) between
the meals.
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2.2. Measurements of Infant Abdominal Adiposity
To assess infant inter-abdominal and subcutaneous-abdominal adiposity, single ultra-
sound measurements were taken with minimal compression with the Aplio XG (Toshiba,
Tokyo, Japan) machine and a high-resolution 14–8 MHz transducer (PLT-1204BX) and
sterile water-based Aquasonic 100 US transmission gel (Parker Laboratories Inc., Fairfield,
NJ, USA). Infants were in supine position for the measurements.
The thicknesses of the preperitoneal and subcutaneous fat (visceral depth (VD) and
subcutaneous-abdominal depth (SAD)) were measured in the upper abdomen of infants
using a previously validated protocol [12]. For both depths the transducer was positioned
where the mid sagittal line intercepts the waist circumference measurement plane, mea-
surements were taken during expiration. VD was measured in the longitudinal plane
(probe depth 9 cm) and was determined as the distance between the corpus of the lumbar
vertebra and the peritoneal boundary. SAD was measured at the same location, but in the
transverse plane (probe depth 4 cm), and determined as the distance between the linea
alba and the cutaneous boundary. Depths were measured directly from the images on the
screen using electronic calipers. Ratios of VD to SAD (VD/SAD) were calculated.
The areas of the subcutaneous and preperitoneal fat (subcutaneous-abdominal fat area
(SFA) and preperitoneal fat area (PFA)) were measured using a standardized protocol for
infants [18]. This method has been validated against computed tomography and is a valid
method for epidemiological studies [19]. It accounts for age specific differences in infant
anatomy, not only measuring the thickness of the fat layers but introducing areas of specific
fat depots, ratios of which are highly correlated with metabolic profile in adults [20]. A
linear transducer was positioned perpendicular to the skin surface on the median upper
abdomen, scans were conducted longitudinally from the xiphoid process to the navel along
the linea alba. Distances from linea alba and (a) to the peritoneum on top of the liver, and
(b) to the inner surface of subcutaneous tissue were measured directly from the images
on the screen using electronic calipers to calculate the SFA and PFA of 2 cm length along
the midline, starting from the reference point in direction of navel. Ratios of PFA to SFA
(PFA/SFA) were calculated. All of the measurements were performed by one experienced
sonographer with previously reported high intra-rater reliability [21].
2.3. Measurements of Maternal Body Composition
Maternal BC (fat-free mass (FFM), FM, %FM) was measured with bioelectrical impedance
spectroscopy with the Impedimed SFB7 bioelectrical impedance analyzer (ImpediMed, Bris-
bane, QLD, Australia) according to the manufacturer’s instructions as described previ-
ously [22]. The within participant coefficient of variation (CV) for maternal %FM of 0.21% has
been reported previously [23]. We also calculated the indices of mothers height-normalized BC:
FFM index (FFMI) as FFM/length2; FM index (FMI) as FM/length2, expressed as kg/m2 [24].
2.4. Measurements of Human Milk Components
The fully described methods along with measured concentrations, CDI and assays’ detec-
tion limits and inter-assay coefficients of variation have been published previously [23,25–29].
In total, we have assessed eleven HM components.
Briefly, pre- and post-feed samples were pooled and defatted for measuring HM
components [30] when required by the method with the exception of adiponectin [23] and
leptin [25], which were measured in whole milk using ELISA. Casein and whey proteins
were separated as described by Kunz and Lonnerdal [31] and Khan et al. [32]. Concentra-
tions of total protein, casein, and whey protein were measured using the Bradford Protein
assay [33]. Lactose was measured in pre- and post-feed samples using the enzymatic-
spectrophotometric method [33] and averaged for analysis. To determine total carbohy-
drates (TCH) skim HM was deproteinized with trichloroacetic acid [34] and dehydrated
by sulfuric acid [35]. Lysozyme was measured by a modification of Selsted and Martinez
method [36,37], and lactoferrin and sIgA were determined by ELISA [37,38]. Standard
assays were adapted for and carried out using a JANUS workstation (PerkinElmer, Inc.,
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Waltham, MA, USA) and measured on EnSpire (PerkinElmer, Inc., Waltham, MA, USA).
All measurements were conducted in duplicate and averaged for analysis. The total HM
oligosaccharide (HMO) concentration was estimated by deducting lactose concentration
from TCH concentration.
24-h milk intake values from the 24-h test-weighing [16], and component concen-
trations measured in HM samples taken at the study sessions were used to determine
calculated daily intakes (CDI), considered representative of a typical daily intake for that
time point.
2.5. Statistical Analyses
The design for the study along with statistical analyses have been previously described
in detail [22,26–28]. In this longitudinal study, milk samples were collected and infants
were measured at 2, 5, 9 and 12 months. An approximate sample size of 14 participants,
that would give study power of 0.80 for detection of effect size of 0.15, was calculated in
G*Power [39] as for a cross-sectional study, since there is no closed form expression suitable
for the calculation of sample sizes for this research design [40], with the consideration
that longitudinal study design is more powerful than cross-sectional. Recruitment of
participants at the 5-month point was shortly introduced, as at 2 months many mothers
would not commit to a study that required to breastfeed to 12 months of age, and the
sample size revised upwards (Figure A1).
Given the longitudinal nature of the data, the relationships were analyzed using
linear mixed effects models, and all models had a random effect for each participant to
account for the structure in the data. Fitted models included (as explanatory variable
and response): (a) infant abdominal fat measures and HM components’ concentrations;
(b) abdominal fat measures and CDI of HM components; (c) abdominal fat measures and
breastfeeding parameters (24-h milk intake, breastfeeding frequency); and (d) abdominal
fat measures and maternal BC parameters. To study the changes over time the models
included infant age (as a categorical variable) interacted with the explanatory variable of
interest as fixed effects. The p-value associated with the interaction was examined, and if
it was below 0.05 the results were reported for the full model (fixed effects for infant age,
the explanatory variable of interest and the interaction); otherwise results were reported
for the model fitted without interaction (fixed effects for infant age and the explanatory
variable of interest only).
The analyses for systematic differences between measured variables at different time
postpartum used linear mixed model with age as a fixed factor and participant as a random
factor. Differences between time points were analyzed using general linear hypothesis tests
(Tukey’s all pair comparisons).
Missing data was dealt with using available case analysis. A false discovery rate (FDR)
adjustment was applied to the subgroupings of results to the interaction p value if it was less
than 0.05 or to the main effect p value [41]. The largest examined p value that is significant
and all p values before that were considered as significant. The adjusted significance levels
are reported in the Tables and set at the 5% level otherwise. Descriptive statistics are
reported as mean ± standard deviation (SD) and range; modelling results as parameters
estimates ± standard error (SE). Statistical analysis and graphics were performed in R 3.1.5.
3. Results
3.1. Subjects
Participants demographics, maternal and infant BC, anthropometrics and breastfeed-
ing parameters (24-h milk intake, 24-h breastfeeding frequency, self-reported breastfeeding
frequency) as well as attrition and missing data have been published recently [22,26–29].
Demographic, anthropometric, and breastfeeding parameters measured at the study ses-
sions and the sample sizes at each time point are presented in Table 1. The missing data
also included: (a) from the 80 expected, due to the missed visits and infant compliance,
measurements of SAD (n = 12), VD (n = 15), PFA and SFA (n = 19); (b) from the 60 expected,
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CDI of casein, whey and total protein, lactose, adiponectin, leptin, lactoferrin and sIgA
(n = 27); CDI of total carbohydrates and HMO (n = 28); and lysozyme CDI (n = 30). The
missing data were spread across the time points (Table 1, Figure A1).
Table 1. Participant anthropometric, abdominal adiposity and breastfeeding characteristics.
Characteristics









Mothers (n = 14) (n = 20) (n = 18) (n = 18)
Weight (kg) 78.8 ± 19.3
a 70.1 ± 17.8 63.0 ± 10.0 64.2 ± 17.3
(57.5–116.2) (53.7–115.3) (50.4–121.9) (51.4–121.9)
BMI (kg/m2)
27.2 ± 5.5 24.8 ± 5.0 22.7 ± 3.9 23.9 ± 5.9
(20.4–35.5) (19.0–35.2) (17.9–37.2) (18.2–37.2)
Infants (n = 15) (n = 20) (n = 19) (n = 18)
Sex (M/F) 9 M/6 F 10 M/10 F 10 M/9 F 9 M/9 F
Age (months) 2.04 ± 0.14 5.16 ± 0.22 9.22 ± 0.27 12.26 ± 0.28
(1.87–2.33) (4.77–5.47) (8.83–9.77) (11.63–12.67)
Length (cm) 58.1 ± 1.9 64.8 ± 2.3 71.7 ± 1.9 73.6 ± 3.2
(54.2–60.0) (60.5–69.5) (66.0–74.0) (69.0–78.5)
Weight (kg) 5.63 ± 0.66 7.431 ± 1.134 8.836 ± 0.975 9.650 ± 0.618
(4.420–7.400) (5.808–9.510) (6.675–10.095) (7.165–11.085)
BMI (kg/m2)
16.6 ± 1.2 17.6 ± 1.9 17.7 ± 1.7 17.8 ± 0.9
(14.5–18.1) (14.9–20.4) (14.2–20.2) (13.7–19.2)
VD (mm)
68.8 ± 9.7 63.3 ± 6.7 66.9 ± 10.3 71.3 ± 12.3
(56.1–87.5) (49.7–80.4) (53.5–95.7) (46.9–100.3)
SAD (mm)
4.0 ± 1.8 5.3 ± 1.8 ** 4.6 ± 2.1 3.7 ± 1.9 **
(1.5–7.2) (2.5–8.7) (2.1–8.4) (1.4–8.5)
VD/SAD ratio
22.0 ± 14.2 * 13.0 ± 5.0 *,** 18.0 ± 8.8 22.6 ± 11.5 **
(8.6–58.3) (7.0–25.9) (7.1–33.0) (9.1–42.2)
SFA (cm2)
0.9 ± 0.3 1.1 ± 0.4 0.9 ± 0.3 0.9 ± 0.4
(0.5–1.3) (0.2–1.9) (0.4–1.5) (0.2–1.4)
PFA (cm2)
0.3 ± 0.1 0.5 ± 0.3 0.5 ± 0.5 0.4 ± 0.1
(0.2–0.4) (0.2–1.3) (0.3–1.8) (0.2–0.7)
SFA/PFA ratio
0.3 ± 0.1 0.8 ± 1.3 0.9 ± 1.4 0.6 ± 0.7
(0.1–0.5) (0.2–4.8) (0.2–5.1) (0.2–2.7)
Age (months) 2.04 ± 0.14 5.16 ± 0.22 9.22 ± 0.27 12.26 ± 0.28
(1.87–2.33) (4.77–5.47) (8.83–9.77) (11.63–12.67)
Breastfeeding characteristics
24-h milk intake (g)
n/a b (n = 17) (n = 8) (n = 8)
818.8 ± 204.9 478.3 ± 154.0 451.1 ± 215.7
(498–1185) (300–775) (255–795)
24-h feeding frequency (24-h MP)
n/a b (n = 17) (n = 8) (n = 9)




(n = 11) (n = 19) (n = 17) (n = 13)
2.3 ± 0.4 2.8 ± 0.8 3.7 ± 1.2 5.4 ± 2.9
(1.5–3.0) (1.5–4.0) (2.0–6.0) (2.2–12.0)
BMI, body mass index; M/F, male/female; MP, milk production; n/a not applicable; PFA, preperitoneal fat area; SAD, subcutaneous-
abdominal depth; SAF, subcutaneous-abdominal fat area; SR, self-reported; VD, visceral depth. a Data are mean ± SD and ranges. b 24-h
milk intake and breastfeeding frequency (meals/24-h) were measured between 2 and 5 months (presented at 5 months) and within 2 weeks
of 9 and 12 months. c Maternal self-report (SR) of breastfeeding frequency at the time of the visit as a typical time between meals (e.g., each
2 h). * p < 0.05; ** p < 0.01 indicate significant differences in infant abdominal adiposity measures between the two marked time points.
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3.2. Longitudinal Changes in Infant Abdominal Adiposity
Longitudinal changes in maternal and infant BC, breastfeeding parameters and HM
components concentrations and CDI have been reported previously [22,26–29]. Infant
abdominal adiposity measurements over the first year of lactation are detailed in Table 1.
No significant changes between the time points were seen for VD, PFA, SFA and PFA/SFA
ratio. Infant SAD was significantly lower at 12 months postpartum compared with 5 months
(−1.65 ± 0.52 mm, p = 0.007), whilst VD/SAD ratio was significantly higher at 12 months
compared with 5 months (8.66 ± 2.58, p = 0.004) and lower at 5 months compared with
2 months (−7.46 ± 2.66, p = 0.025).
3.3. Human Milk Components and Infant Abdominal Adiposity
Higher lactoferrin concentrations were differentially associated with infant VD, lower
VD at 2 and 12 months and higher at 5 and 9 months (overall p = 0.003), with no other asso-
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Figure 1. Significant associations between (A) infant visceral depth and lactoferrin concentration
(p = 0.003); and infant subcutaneous fat area (SFA) and calculated daily intakes (CDI) of (B) total
carbohydrates (p = 0.004), (C) lactose (p = 0.013) and (D) total protein (p = 0.013). Lines represent
linear regression and grouped by the month of lactation.
CDI of total protein (p = 0.013), total carbohydrates (p = 0.004) and lactose (p = 0.013)
were positively associated with infant SFA (Table 2, Figure 1).
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3.4. Breastfeeding Parameters and Infant Abdominal Adiposity
Infant 24-h milk intake was positively associated with infant SAD (p = 0.007) and VD
(p = 0.013). The higher 24-h breastfeeding frequency was associated with infant PFA/SFA
ratio; a small increase at 5 months, a small decrease at 9 months and a larger decrease at
12 months (p = 0.002). No other associations for breastfeeding parameters were seen after
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Figure 2. Significant associations between infant subcutaneous fat area (SFA) and (A) maternal weight (p = 0.020), (B) mater-
nal fat mass (p = 0.010) and (C) fat mass index (p = 0.023); 24h milk intake and (D) subcutaneous-abdominal (p = 0.007)
and (E) visceral (p = 0.013) depths; and (F) breastfeeding frequency and peritoneal fat area to subcutaneous fat area ratio
(PFA/SFA, p = 0.002). Lines represent linear regression and grouped by the month of lactation.
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Table 2. Associations between infant abdominal adiposity parameters and concentrations and daily intakes of human milk components.
Predictor








(SE) Slope (SE) Predictor
Infant Age
(Months) Interaction
Concentrations (n = 14) (n = 20) (n = 17) (n = 13) (n = 20)
Subcutaneous-abdominal depth (mm), significance at <0.041 d






(0.112) 0.64 0.038 0.041
b
Visceral depth (mm), significance at <0.019
Lactoferrin, g/L 74.5 (4.93) −11.2(8.85) 61.0 (5.55) 5.61 (12.8) 52.4 (5.49) 23.4 (8.44) 86.9 (8.47)
−24.6
(12.7) 0.70 0.084 0.003








Visceral/subcutaneous-abdominal depths ratio, significance at <0.006
Total protein, g/L −16.2(16.8) 3.55 (1.6) 12.7 (6.61)
0.063
(0.554) 5.6 (11.4) 1.17 (1.08) 48.9 (11.5)
−2.58
(1.07) 0.93 0.003 0.006
Preperitoneal fat area (cm2), significance at <0.013



















(0.50) 0.038 0.045 0.049
Calculated daily intakes (n = 12) (n = 17) (n = 8) (n = 8) (n = 17)
Subcutaneous-abdominal depth (mm), significance at <0.005






(0.0005) 0.094 0.079 0.027
Casein, g 2.66 (0.845) 1.34 (0.555) 3.43 (0.928) 1.34(0.555) 3.98 (0.794) 1.34 (0.555) 2.86 (0.744) 1.34 (0.555) 0.021 0.45 0.91






(0.023) 0.021 0.17 0.27




(8.51) 0.70 0.11 0.029






(0.018) 0.005 0.042 0.16
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Table 2. Cont.
Predictor








(SE) Slope (SE) Predictor
Infant Age
(Months) Interaction













































(0.379) 0.042 0.20 0.44














(0.003) 0.004 0.18 0.20














(0.021) 0.013 0.31 0.81
Preperitoneal/subcutaneous-abdominal fat areas ratio, significance at <0.028
Lactoferrin, g 1.44 (0.828) −2.52(2.28)
0.057




(2.24) 14.2 (7.28) 0.52 0.001 0.028
sIgA, secretory immunoglobulin A. a Data are parameter estimate ± SE (standard error of estimate); effects of predictors taken from linear mixed effects models that accounted for month after birth and an
interaction between month after birth and predictor with a random effect for participant; if the p value for interaction is not <0.05 parameter estimates are taken from a model with no interaction. b,c Results are
presented only for interactions or predictors with raw p values < 0.05. d Significance for the tested combinations after the false discovery rate adjustment (significant p values are indicated by the bold text).
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Table 3. Associations between infant abdominal adiposity and breastfeeding parameters and maternal body composition.
Predictor








(SE) Slope (SE) Predictor
Infant Age
(Months) Interaction
Breastfeeding parameters (n = 17) (n = 7) (n = 8) (n = 17)
Subcutaneous-abdominal depth (mm), significance at <0.005 d






Subcutaneous-abdominal fat area (cm2), significance at <0.022










(0.0004) 0.022 0.24 0.31
Visceral depth (mm), significance at < 0.05
24-h milk intake, g n/a 46.50 (7.35) 0.02 (0.009) 59.00 (5.33) 0.02 (0.009) 56.8 (5.12) 0.02 (0.009) 0.013 0.007 0.068
Preperitoneal fat area (cm2), significance at <0.047
Breastfeeding






(0.059) 0.047 <0.001 0.082
Preperitoneal/subcutaneous-abdominal fat areas ratio, significance at <0.05
Breastfeeding






(0.372) 0.19 <0.001 0.002
c
Maternal body composition (n = 14) (n = 20) (n = 18) (n = 17) (n = 20)
Subcutaneous-abdominal fat area (cm2), significance at <0.048








(0.008) 0.91 0.46 0.010










(0.015) 0.57 0.49 0.019








(0.005) 0.66 0.49 0.020










(0.028) 0.88 0.48 0.023








(0.012) 0.39 0.54 0.048
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Table 3. Cont.
Predictor








(SE) Slope (SE) Predictor
Infant Age
(Months) Interaction
Visceral depth (mm), significance at <0.045






(0.225) 0.65 0.077 0.045
Weight, kg 76.60(11.70)
−0.101




(0.132) 0.48 0.081 0.049
Preperitoneal/subcutaneous-abdominal fat areas ratio, significance at <0.022










(0.026) 0.82 0.35 0.022








(0.016) 0.99 0.37 0.042








(0.045) 0.54 0.35 0.045








(1.39) 0.16 (0.081) 0.046 0.29 0.60
a Data are parameter estimate ± SE (standard error of estimate); effects of predictors taken from linear mixed effects models that accounted for month after birth and an interaction between month after birth and
predictor with a random effect for participant; if the p value for interaction is not <0.05 parameter estimates are taken from a model with no interaction. b,c Results are presented only for interactions or predictors
with raw p values < 0.05. d Significance for the tested combinations after the false discovery rate adjustment (significant p values are indicated by the bold text). e 24-h milk intake and breastfeeding frequency
(meals/24-h) were measured between 2 and 5 months (presented at 5 months) and within 2 weeks of 9 and 12 months.
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3.5. Maternal Body Composition and Infant Abdominal Adiposity
Maternal adiposity (weight, FM, FMI) was negatively associated with infant SFA at 2,
5, 12 months; at 9 months the association was positive (p < 0.05), with no other associations
for maternal BC after the FDR adjustment (Table 3 and Figure 2).
4. Discussion
This pilot longitudinal study points to the possible complex mechanisms by which HM
and breastfeeding may provide some degree of protection from obesity later in life. For the
first time we focused on the effect of doses (daily intakes) of an array of HM components
on infant abdominal adiposity throughout the first year of breastfeeding on demand.
We confirm that in breastfed infant abdominal adipose tissue depots, subcutaneous and
visceral, are differentially regulated during infancy. With no longitudinal changes in
VF during first 12 months and HM components’ CDI associating predominantly with
subcutaneous-abdominal fat depots, these results further inform that breastfeeding and
HM do not largely influence VF over the first year of infant nutrition and indeed may be
protective against obesity. First and foremost, we link HM composition and components’
intake as well as maternal adiposity and breastfeeding parameters to the development of























Figure 3. Suggested pathways of lactocrine programming of the infant abdominal adiposity during
first 12 months postpartum. Associations between tested parameters and infant abdominal adiposity
are indicated by the arrows (green—positive associations; red—negative associations); dotted arrows
indicate time-dependent associations. BF—breastfeeding; CDI—calculated daily intake.
Reportedly, breastfed infants have higher fat accretion compared with formula-
fed [10,42] and non-exclusively breastfed infants [43], speculating that substantial fat
accrual during this period of active growth may be protective against obesity later in life.
As specific location of fat accretion may determine higher metabolic risk [44], it is impera-
tive to investigate if higher fat accretion in the abdominal area in breastfed infants means
more metabolic risk, and if development of these fat depots is independently regulated
in this population and affected by nutrition. Few previous studies have investigated the
link between infant abdominal adiposity and breastfeeding. One study determined lower
VD in 3 and 12-month-old infants that were exclusively breastfed at 3 months [12], al-
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though VD measurements in that cohort (2.3–2.8 cm) were unexplainably smaller than ours
(6.3–7.1 cm, which relate more to abdominal cavity thickness and are similar to the infant
VF thickness measured as distance from the inner face of rectus abdominis muscle to the
anterior wall of the aorta (5.0–5.2 cm) [5]). Another study reported duration of exclusive
breastfeeding was not associated with VF but was positively related to subcutaneous-
abdominal fat at 3 and 6 months and %FM at 6 months [14]. The third study showed
no difference in both subcutaneous-abdominal and preperitoneal fat thicknesses between
breastfed and formula-fed infants [13]. The most recent study investigated the effect of HM
macronutrient composition reporting positive relationships between HM fat concentration
(measured in post-feed sample which is the most varied between women and feeds) and
infant subcutaneous-abdominal fat thickness, and negative between protein concentration
and VF thickness [15]. These results suggest independent regulation of the visceral and
subcutaneous-abdominal fat depots in this population.
Although important factors, the presence and duration of any breastfeeding and
exclusive breastfeeding are categorical variables usually self-reported by parents. We
have measured the actual milk intakes and daily intakes of HM components that infants
received with milk to assess the dose effect of these components on development of infant
abdominal adiposity. Whilst there are no studies of such design, our findings of time-
dependent differential effects of daily intakes of HM macronutrients and bioactive proteins
together with breastfeeding parameters further explain the effect of breastfeeding on infant
adipose tissue depots.
In line with our previous studies, we found very few associations for the concentra-
tions of HM components, with the only lactoferrin concentration association with infant
VD (negative at 2 and 12 months and positive at 5 and 9 months) remaining after multiple
comparisons adjustment (Table 2). This is worthy of attention as we previously did not find
any associations between lactoferrin concentration and infant BC [29]. This finding is fur-
ther strengthened with the elucidation of weak time-dependent associations of lactoferrin
CDI with preperitoneal adiposity (prior to FDR; Table 2). These associations were negative
at 2 and 9 months and positive at 5 and 12 months. We have previously shown lactoferrin
CDI to be negatively associated with infant FFMI throughout the first year of lactation
in the same cohort [29] emphasising the importance of lactoferrin in the development of
BC in breastfed infants. Bovine lactoferrin-supplemented formula is linked to somewhat
contrasting results at various time points during first year of life, showing either positive
associations with infant length (4–6 months) and weight (6 months) [45], and both, negative
association with weight growth rate in female infants [46] and no association with infant
growth parameters [47] during the first 12 months. These results support our findings
indicating that lactoferrin, including bovine lactoferrin, may have time-dependent effect on
infant growth and adiposity during infancy as well as dose-dependent effect, as previously
reported for bovine lactoferrin in in vitro studies [48], in which lactoferrin, depending on
the dose, either increased or reduced proliferation of porcine intestinal epithelial cells.
Similar to lactoferrin, adiponectin, lysozyme and sIgA concentrations and CDI of
adiponectin and sIgA showed similar time-dependent and predominately negative rela-
tionships with abdominal adiposity (prior to FDR, Table 2). Recently we reported weak
time-dependent associations between infant whole body adiposity and lysozyme con-
centration [29] and positive relationships with both, lysozyme CDI [29] and adiponectin
CDI [26]. Our findings suggest that these bioactive molecules may have multiple timely
functions as well as dose-dependent effects on regulation of development of abdominal fat
depots and thus, potentially influence risk of obesity later in life. Further larger studies will
elucidate the effect of these bioactive HM components on the development and regulation
of infant abdominal adiposity.
Unlike the bioactive proteins, CDI of the major HM macronutrients were positively
associated with infant subcutaneous-abdominal adiposity at all-time points (Table 2), with
casein also displaying a weak positive association with both subcutaneous-abdominal
adiposity parameters. Previously we have not observed strong associations between HM
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total protein and infant whole body adiposity, yet reported a positive association with
HM casein [27]. Furthermore, higher CDI of total carbohydrates and lactose were posi-
tively associated with multiple whole body adiposity parameters in the same cohort [28].
These results are supportive of each other as different BC assessment techniques were
used (bioimpedance spectroscopy and ultrasound skinfolds) as well as different anatomical
skinfold sites. Our findings indicate that within the normal developmental context of breast-
feeding HM major macronutrients promote the development of subcutaneous-abdominal
rather than visceral adiposity. This is supported by an earlier study that reported higher
%FM in exclusively breastfed infants and higher %FM, subcutaneous but not VF, with
longer duration of breastfeeding [14], proposing an advantageous adipose phenotype of
breastfed infants, associated with a reduced risk of NCD [44].
The associations of macronutrients CDI with subcutaneous-abdominal adiposity paral-
lel the associations of infant breastfeeding parameters and abdominal adiposity. Previously,
we have reported that 24-h milk intake was positively associated with infant FM [22]. In the
current study, 24-h milk intake also showed positive associations with both, subcutaneous-
abdominal adiposity and VD (Table 3). Conversely, breastfeeding frequency, despite being
positively related to 24-h milk intake [22], was mainly negatively associated with visceral
adiposity (preperitoneal fat area measurements), supporting the necessity of breastfeeding
on demand.
Maternal adiposity has been proposed to impact infant adiposity via several mech-
anisms during both pregnancy [49] and lactation [50]. Our study showed that higher
maternal weight and adiposity are associated negatively with infant subcutaneous adipos-
ity (Table 3), suggesting that higher maternal adiposity may limit the protective effect of
breastfeeding against obesity later in life. One recent study reported no associations of
maternal adiposity with 3-6-month-old infants’ abdominal adiposity, both subcutaneous
and visceral, but only proxy adiposity measurements, maternal pre-pregnancy BMI and
weight gain, were used in analysis [14]. Whilst participants in our study displayed similar
variations in BMI to the previous study, we followed the dyads for a longer period and
measured actual maternal BC.
This pilot study focused on dyads that were breastfeeding on demand for 12 months,
thus is more reflective of normal lactation and development of infant abdominal adiposity.
The strong points of this study are the longitudinal measurements of dyads and sampling of
HM, accounting for the dose (intake) of HM components, measuring maternal BC and the
wide variation in maternal adiposity. The limitations are the modest sample size associated
with the multiple measurement time points and the small number of 24-h milk intake
measurements at 9 and 12 months postpartum. The preperitoneal fat measurements are
the proxy estimations of VF and may be prone to higher measurement error, leading to
underestimated associations. A substantial accrual of preperitoneal fat occurs after 2 years
of age [18], so measurements and associations of preperitoneal fat in our study may not
necessarily be predictive of abdominal adiposity later in life. Our sample is relatively
homogenous (predominantly Caucasian, term, healthy breastfed singletons from urban
mothers of higher social-economic status), thus our results may not be transferable to
populations that are more diverse.
5. Conclusions
The findings from this pilot study highlight the complex mechanisms by which
breastfeeding and HM may provide some degree of protection from obesity and reduce
risk factors for NCD later in life. The time-dependent differential associations of daily
intakes of HM macronutrients and bioactive proteins, as well as breastfeeding parameters
and maternal adiposity, with the development of infant abdominal adiposity during the
first year of life indicate a potential to improve infant outcomes via interventions, such
as extending the duration of breastfeeding to the first year and presumably beyond, and
improving maternal BC pre-conception and during pregnancy and lactation.
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